TTrialPathMatch Me to Trials
← Back to trials
RecruitingSpinal Cord InjuriesBlood Pressure Disorders

ARC-IM System to Manage Symptomatic Blood Pressure Instability Secondary to Chronic Spinal Cord Injury

Eligible age

18–75 yrs

Accepts

All genders

Locations

10 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Empower BP is a pivotal, interventional, multicenter, prospective, randomized, controlled double-blinded study to evaluate the safety and effectiveness of the ARC-IM System in managing symptomatic blood pressure instability in individuals with chronic SCI (\>1 year after SCI). The primary effectiveness outcome will be evaluated through subject-reported ADFSCI and seated blood pressure assessments at 3 months post-implant. Following a baseline screening period and the surgical implantation of the ARC-IM System, subjects will be randomized with a 2:1 ratio into an active or control arm for 3 months. All the subjects will undergo therapy activation sessions (into either Group 1: active intervention, or Group 2: intervention aimed to mimic the active intervention without the active component) within 21 days of the surgical implant and will then commence independent at-home use of ARC-IM Therapy. At the 3 Month timepoint, after all assessments are conducted, all subjects will transition to the open-label period in order to receive the active version of the ARC-IM System in an open-label fashion. All subjects will undergo therapy programming sessions following Month 3.

Sponsor: ONWARD Medical, Inc.

You may qualify if…

  • 1. Aged 18 years or above, and no older than 75 years at the time of enrollment.
  • 2. Clinical evidence of Orthostatic Hypotension (blood pressure drop of 20mmHg systolic or 10mmHg diastolic) measured during Head Up Tilt Table assessment (HUTT, within 10 minutes) with current standard of care if any. 2 out of 3 tests must meet OH criteria.
  • 3. Clinical evidence of sustained hypotension (average systolic Blood pressure ≤ 110 mmHg) when measured each minute for 10 minutes while seated and in the absence of supportive compressive garments and medication.
  • 4. Evidence of symptomatic hypotension as determined by a non-zero OHSA total score
  • 5. A Spinal cord injury at the neurologic level between C2 and T6 inclusive.
  • 6. American Spinal Injury Association (ASIA) Impairment Scale (AIS) classification A, B, C, or D.
  • 7. Traumatic (non-progressive) chronic spinal cord injury with minimum 12 months post-injury prior to study entry.
  • 8. Average A-P diameter of the sponal canal ≥ 13 mm, measured on MRI at the disc space at level(s) planned for implantation

You may not qualify if…

  • 1. Subject has an autoimmune etiology of spinal cord dysfunction/injury.
  • 2. Subject has diseases and conditions that would increase the morbidity and mortality of the surgical procedures required by the study.
  • 3. Subject has a history of physiologic hypotension prior to SCI
  • 4. Subject has a history of unexpected blood pressure instability related to medications
  • 5. Inability to withhold antiplatelet/anticoagulation agents perioperatively.
  • 6. History of myocardial infarction or cerebrovascular event within the past 6 months. or
  • 7. History of chronic/recurrent severe cardiac arrythmias (e.g., ventricular tachycardia, ventricular fibrillation, third degree atrioventricular block)
  • 8. Evidence of clinically significant underlying cardiac conditions on Holter monitoring performed at screening including but not limited to arrhythmias (e.g., atrial fibrillation, ventricular tachycardia),

Where it's recruiting

Arkansas

Little Rock

Colorado

Englewood

Florida

Miami

Georgia

Atlanta

Kentucky

Louisville

Maryland

Baltimore

Massachusetts

Cambridge

Minnesota

Rochester

New York

New York · The Bronx

Oregon

Portland

Source: ClinicalTrials.gov · NCT07147296 · last updated 2026-06-16